Sara Stetson
Family · Anchorage, AKNPI 1124491501
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.7% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 33.0% of the total. 2025 is the largest year on record at $599, 2.7 times the $224 reported in 2021.
Across 93 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$622
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$352
- AstraZeneca$204
- Pfizer$130
- Astellas Pharma US Inc$122
- Novo Nordisk$110
- plus $344 from 11 others
What the payments were for
- Food & beverage$1,78695%
- Education$995%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $622 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $352 |
| AstraZeneca | 11 | $204 |
| Pfizer | 7 | $130 |
| Astellas Pharma US Inc | 2 | $122 |
| Novo Nordisk | 6 | $110 |
| Galderma Laboratories, L.p. | 3 | $63 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| Antares Pharma, Inc. | 2 | $43 |
| Exact Sciences | 2 | $41 |
| Biohaven Pharmaceuticals, Inc. | 2 | $37 |
| Acelrx Pharmaceuticals, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $13 |
How this compares
$1,885 in reported general payments places this provider in the 85th percentile of 315 family providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $81,913 |
| MounjaroTirzepatide | 62 | $71,159 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $33,245 |
| EliquisApixaban | 17 | $29,262 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $18,842 |
| XyostedTestosterone Enanthate | 22 | $17,677 |
| Nurtec OdtRimegepant Sulfate | 18 | $17,366 |
| MyrbetriqMirabegron | 57 | $16,655 |
| QuliptaAtogepant | 14 | $14,775 |
| SynthroidLevothyroxine Sodium | 63 | $7,763 |
| OxycontinOxycodone Hcl | 11 | $4,911 |
| Testosterone | 49 | $4,774 |
| Testosterone Cypionate | 35 | $4,763 |
| ProgesteroneProgesterone, Micronized | 120 | $4,605 |
| Pantoprazole Sodium | 67 | $4,036 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $110 | $81,91360 claims |
| Lilly USA, LLCMounjaro | $20 | $71,15962 claims |
| PfizerEliquis, Nurtec Odt | $130 | $46,62835 claims |
| AbbVieQulipta, Synthroid | $622 | $22,53977 claims |
| AstraZenecaBreztri Aerosphere | $204 | $18,84225 claims |
| Antares Pharma, Inc.Xyosted | $43 | $17,67722 claims |
| Astellas Pharma US IncMyrbetriq | $122 | $16,65557 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 315 family providers in Alaska.
Other family in Anchorage
- Erica HeagyAnchorage$249K
- Trisha KernodleAnchorage$60K
- Marisha DietersAnchorage$6K
- Christine HooverAnchorage$6K
- Leigh KeeferAnchorage$5K
- Sara GeraciAnchorage$4K
- Christine SaganAnchorage$4K
- Bethany BuchananAnchorage$4K
- Natasha SherrillAnchorage$4K
- Katherine HardyAnchorage$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.